View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 9, 2021

Womed’s fertility-preserving intrauterine device obtains CE mark 

Womed Leaf is a soft film mechanical barrier that shields the uterine cavity for a week to protect against intrauterine adhesion.

Women’s health tech company Womed has obtained CE mark for its fertility-preserving intrauterine device, Womed Leaf, for the treatment and prevention of bonding of the uterine walls after surgical intervention.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Womed Leaf is the first-ever mechanical barrier against intrauterine adhesion (IUA ) and is composed of a soft film that shields the complete uterine cavity for a week.

After this, the device is discharged naturally and painlessly.

Womed Leaf was analysed during the first trial of the company’s PREG1 clinical programme, which enrolled 23 subjects who were scheduled to undergo hysteroscopic myomectomy.

Results from the clinical trial showed that Womed Leaf was safe and efficient in averting IUA in women with uterine fibroids undergoing hysteroscopic myomectomy.

Furthermore, device manipulation was under two minutes in all cases with the procedure termed to be easy by all operators.

None of the subjects experienced any injuries, reactions or adverse events linked to the device.

Womed Leaf caused zero to slight discomfort for patients and efficiently averted adhesion formation in 83% of women at six weeks.

IUAs occur following 20% to 45% of surgical procedures when the uterine walls attach together because of abnormal scarring.

It is a key cause of infertility and recurrent miscarriages, being responsible for one in five miscarriages, the company noted.

To prevent the formation of IUA , obstetrician-gynaecologists need to keep the uterine walls separated following an intrauterine procedure.

IUA treatment, with a relapse rate of 60%, leaves women concerned about their chances of conceiving.

Womed co-founder and executive chairman Gonzague Issenmann said: “Womed Leaf represents a major breakthrough in helping women preserve or recover their fertility from the heartbreaking condition of IUA , and we are thrilled by its clinical results and CE mark approval.

“We now feel confident to carry out our ambitious strategy: to leverage Womed ’s proprietary polymer technology and develop a portfolio of unique intrauterine drug delivery products to safely treat challenging uterine pathologies, like acute bleeding and endometriosis.”

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network